International Journal of High Risk Behaviors and Addiction

Published by: Kowsar

Iran’s Activities on Prevention, Treatment and Harm Reduction of Drug Abuse

Mohammad Bagher Saberi Zafarghandi 1 , Mohsen Jadidi 2 , * and Narjes Khalili 3
Authors Information
1 Department of Addiction, Mental Health Research Center, School of Behavioral Sciences and Mental Health, Tehran Institute of Psychiatry, Iran University of Medical Sciences, Tehran, IR Iran
2 Department of Psychology, Bandargaz Branch, Islamic Azad University, Bandargaz, IR Iran
3 Drug Control Headquarters, Presidency of Islamic Republic of Iran, Tehran, IR Iran
Article information
  • International Journal of High Risk Behaviors and Addiction: December 2015, 4 (4); e59737
  • Published Online: December 1, 2015
  • Article Type: Review Article
  • Received: August 17, 2014
  • Revised: March 28, 2015
  • Accepted: April 28, 2015
  • DOI: 10.5812/ijhrba.22863

To Cite: Saberi Zafarghandi M B, Jadidi M, Khalili N. Iran’s Activities on Prevention, Treatment and Harm Reduction of Drug Abuse, Int J High Risk Behav Addict. 2015 ;4(4):e59737. doi: 10.5812/ijhrba.22863.

Abstract
Copyright © 2015, Zahedan University of Medical Sciences.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnote
References
  • 1. Sussman S, Sussman AN. Considering the definition of addiction. Int J Environ Res Public Health. 2011; 8(10): 4025-38[DOI][PubMed]
  • 2. Chen CY, Lin KM. Health consequences of illegal drug use. Curr Opin Psychiatry. 2009; 22(3): 287-92[PubMed]
  • 3. Alam Mehrjerdi Z. Crystal in Iran: methamphetamine or heroin kerack. Daru. 2013; 21(1): 22[DOI][PubMed]
  • 4. Kato I, Zeleniuch-Jacquotte A, Toniolo PG, Akhmedkhanov A, Koenig K, Shore RE. Psychotropic medication use and risk of hormone-related cancers: the New York University Women's Health Study. J Public Health Med. 2000; 22(2): 155-60[PubMed]
  • 5. Challier B, Chau N, Predine R, Choquet M, Legras B. Associations of family environment and individual factors with tobacco, alcohol, and illicit drug use in adolescents. Eur J Epidemiol. 2000; 16(1): 33-42[PubMed]
  • 6. Torrens M, Domingo-Salvany A, Alonso J, Castillo C, San L. Methadone and quality of life. Lancet. 1999; 353(9158): 1101[DOI][PubMed]
  • 7. Virk S, Schwartz TL, Jindal S, Nihalani N, Jones N. Psychiatric medication induced obesity: an aetiologic review. Obes Rev. 2004; 5(3): 167-70[DOI][PubMed]
  • 8. World Drug Report, Sales No. E.11.XI.10. Vienna; United Nations Publication. 2011;
  • 9. Kulsudjarit K. Drug problem in southeast and southwest Asia. Ann N Y Acad Sci. 2004; 1025: 446-57[DOI][PubMed]
  • 10. Iranian Drug Control Headquarter IP . National Rapid Situation Analysis of Drug Abuse Status in Iran. 2007;
  • 11. Zerell U, Ahrens B, Gerz P. Documentation of a heroin manufacturing process in Afghanistan. Bull Narc. 2005; 57(1-2): 11-31[PubMed]
  • 12. Meysamie A, Sedaghat M, Mahmoodi M, Ghodsi SM, Eftekhar B. Opium use in a rural area of the Islamic Republic of Iran. East Mediterr Health J. 2009; 15(2): 425-31[PubMed]
  • 13. UNODC global vision on prevention, treatment and care of drug abuse and HIV/AIDS. 2012;
  • 14. Shekarchizadeh H, Ekhtiari H, Khami MR, Virtanen JI. Patterns of pre-treatment drug abuse, drug treatment history and characteristics of addicts in methadone maintenance treatment in Iran. Harm Reduct J. 2012; 9: 18[DOI][PubMed]
  • 15. Daneshmandan N, Narenjiha H, Tehrani K, Assari S, Khoddami-Vishteh HR. Initiation to the first drug use among substance-dependent persons in Iran. Subst Use Misuse. 2011; 46(9): 1124-41[DOI][PubMed]
  • 16. Momtazi S, Rawson R. Substance abuse among Iranian high school students. Curr Opin Psychiatry. 2010; 23(3): 221-6[DOI][PubMed]
  • 17. De La Haye W. Community-based prevention of substance abuse. West Indian Med J. 2004; 53(6): 420-3[PubMed]
  • 18. 2012 World Drug Report, Sales No. E.12.XI.1. Vienna;. 2012;
  • 19. 2013 World Drug Report, Sales No. E.13.XI.6. Vienna;. 2013;
  • 20. Mojtahedzadeh V, Razani N, Malekinejad M, Vazirian M, Shoaee S, Saberi Zafarghandi MB, et al. Injection drug use in Rural Iran: integrating HIV prevention into iran's rural primary health care system. AIDS Behav. 2008; 12(4 Suppl)-12[DOI][PubMed]
  • 21. dvanced Training for Youth leaders and Workshop on the Development of Manual for Drug Abuse Prevention among Iranian Youth 1st Batch.
  • 22. Vazirian M. Review of drug demand reduction programs in Iran: Advices for development and strategic planning. Soc Welfare. 2003; 3: 145-201
  • 23. Sharifi H, Kharaghani R, Sigari S, Emami H, Sadr M, Masjedi M. Common methods to treat addiction in treatment- rehabilitation centers in tehran. Iran J Public Health. 2012; 41(4): 63-8[PubMed]
  • 24. AIDS Progress Report On Monitoring of the United Nations General Assembly Special Session on HIV and AIDS. 2012;
  • 25. Haghdoost AA, Mostafavi E, Mirzazadeh A, Navadeh S, Feizzadeh A, Fahimfar N, et al. Modelling of HIV/AIDS in Iran up to 2014. J AIDS HIV Res. 2011; 3(12): 231-9
  • 26. Schoenbaum EE, Hartel D, Selwyn PA, Klein RS, Davenny K, Rogers M, et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med. 1989; 321(13): 874-9[DOI][PubMed]
  • 27. Farrell M, Ward J, Mattick R, Hall W, Stimson GV, des Jarlais D, et al. Methadone maintenance treatment in opiate dependence: a review. BMJ. 1994; 309(6960): 997-1001[PubMed]
  • 28. Hutchinson SJ, Taylor A, Gruer L, Barr C, Mills C, Elliott L, et al. One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme. Addiction. 2000; 95(7): 1055-68[PubMed]
  • 29. Wright NM, French C, Allgar V. The safe implementation of a prison-based methadone maintenance programme: 7 year time-series analysis of primary care prescribing data. BMC Fam Pract. 2014; 15: 64[DOI][PubMed]
  • 30. Rafiey H, Narenjiha H, Shirinbayan P, Noori R, Javadipour M, Roshanpajouh M, et al. Needle and syringe sharing among Iranian drug injectors. Harm Reduct J. 2009; 6: 21[DOI][PubMed]
  • 31. Noori R, Narenjiha H, Aghabakhshi H, Habibi G, Khoshkrood Mansoori B. Methadone maintenance therapy outcomes in Iran. Subst Use Misuse. 2012; 47(7): 767-73[DOI][PubMed]
  • 32. Kaiser HJ. Praise for Iran's Harm Reduction Program. 2010;
  • 33. Des Jarlais DC, Hagan H, Friedman SR, Friedmann P, Goldberg D, Frischer M, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. Jama. 1995; 274(15): 1226-31[PubMed]
  • 34. Hagan H, Jarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health. 1995; 85(11): 1531-7[PubMed]
  • 35. Vlahov D, Junge B, Brookmeyer R, Cohn S, Riley E, Armenian H, et al. Reductions in high-risk drug use behaviors among participants in the Baltimore needle exchange program. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 16(5): 400-6[PubMed]
  • 36. Drucker E, Lurie P, Wodak A, Alcabes P. Measuring harm reduction: the effects of needle and syringe exchange programs and methadone maintenance on the ecology of HIV. AIDS. 1998; 12 Suppl A-30[PubMed]
  • 37. Dolan K, Salimi S, Nassirimanesh B, Mohsenifar S, Allsop D, Mokri A. Characteristics of Iranian women seeking drug treatment. J Womens Health (Larchmt). 2011; 20(11): 1687-91[DOI][PubMed]
  • 38. Fahimfar N, Sedaghat A, Hatami H, Kamali K, Gooya M. Counseling and Harm Reduction Centers for Vulnerable Women to HIV/AIDS in Iran. Iran J Public Health. 2013; 42: 98-104[PubMed]
  • 39. Stoicescu C. The Global State of Harm Reduction 2012: Towards an Integrated Response. 2012;
  • 40. Hahn EJ, Simpson MR, Kidd P. Cues to parent involvement in drug prevention and school activities. J Sch Health. 1996; 66(5): 165-70[PubMed]
  • 41. Sussman S. Development of a school-based drug abuse prevention curriculum for high-risk youths. J Psychoactive Drugs. 1996; 28(2): 169-82[DOI][PubMed]
  • 42. Ishaak F, de Vries NK, van der Wolf K. Test implementation of a school-oriented drug prevention program "Study without Drugs": pre- and post-testing for effectiveness. BMC Public Health. 2014; 14: 590[DOI][PubMed]
  • 43. Mihalic SF, Fagan AA, Argamaso S. Implementing the LifeSkills Training drug prevention program: factors related to implementation fidelity. Implement Sci. 2008; 3: 5[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments